We’re always interested in working with new investment firms.
Inozyme Pharma is backed by a syndicate of premier life sciences investors, including:
Longitude Capital specializes in making venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs.Learn More
NEA invests in visionary entrepreneurs that are at the helm of current and future industry leaders, fueling the development of technologies that will keep the U.S. at the forefront of innovation.Learn More
Working out of Copenhagen, with affiliates in San Francisco and Boston, Novo Holdings is a world-leading life science investor with a focus on creating long-term value. Novo Holdings invests the wealth of the Foundation in life science investments, which includes investing in life science companies at all stages of development and financial investments, which manages a diversified portfolio of equity and fixed income securities.Learn More